QQQ   269.21 (-0.84%)
AAPL   447.31 (+0.64%)
MSFT   207.80 (-2.20%)
FB   263.54 (-1.83%)
GOOGL   1,488.98 (-0.63%)
AMZN   3,132.80 (-1.09%)
NVDA   445.25 (-0.61%)
CGC   18.14 (+9.08%)
BABA   247.17 (-1.96%)
TSLA   1,423.20 (-2.03%)
MU   48.99 (+0.49%)
GE   6.66 (+3.90%)
AMD   81.58 (-3.85%)
T   30.13 (+0.37%)
F   7.09 (+3.35%)
ACB   10.17 (-0.97%)
GILD   68.29 (-1.53%)
NFLX   484.82 (-2.00%)
DIS   129.55 (-0.29%)
BAC   26.66 (+2.11%)
BA   177.74 (+4.54%)
QQQ   269.21 (-0.84%)
AAPL   447.31 (+0.64%)
MSFT   207.80 (-2.20%)
FB   263.54 (-1.83%)
GOOGL   1,488.98 (-0.63%)
AMZN   3,132.80 (-1.09%)
NVDA   445.25 (-0.61%)
CGC   18.14 (+9.08%)
BABA   247.17 (-1.96%)
TSLA   1,423.20 (-2.03%)
MU   48.99 (+0.49%)
GE   6.66 (+3.90%)
AMD   81.58 (-3.85%)
T   30.13 (+0.37%)
F   7.09 (+3.35%)
ACB   10.17 (-0.97%)
GILD   68.29 (-1.53%)
NFLX   484.82 (-2.00%)
DIS   129.55 (-0.29%)
BAC   26.66 (+2.11%)
BA   177.74 (+4.54%)
QQQ   269.21 (-0.84%)
AAPL   447.31 (+0.64%)
MSFT   207.80 (-2.20%)
FB   263.54 (-1.83%)
GOOGL   1,488.98 (-0.63%)
AMZN   3,132.80 (-1.09%)
NVDA   445.25 (-0.61%)
CGC   18.14 (+9.08%)
BABA   247.17 (-1.96%)
TSLA   1,423.20 (-2.03%)
MU   48.99 (+0.49%)
GE   6.66 (+3.90%)
AMD   81.58 (-3.85%)
T   30.13 (+0.37%)
F   7.09 (+3.35%)
ACB   10.17 (-0.97%)
GILD   68.29 (-1.53%)
NFLX   484.82 (-2.00%)
DIS   129.55 (-0.29%)
BAC   26.66 (+2.11%)
BA   177.74 (+4.54%)
QQQ   269.21 (-0.84%)
AAPL   447.31 (+0.64%)
MSFT   207.80 (-2.20%)
FB   263.54 (-1.83%)
GOOGL   1,488.98 (-0.63%)
AMZN   3,132.80 (-1.09%)
NVDA   445.25 (-0.61%)
CGC   18.14 (+9.08%)
BABA   247.17 (-1.96%)
TSLA   1,423.20 (-2.03%)
MU   48.99 (+0.49%)
GE   6.66 (+3.90%)
AMD   81.58 (-3.85%)
T   30.13 (+0.37%)
F   7.09 (+3.35%)
ACB   10.17 (-0.97%)
GILD   68.29 (-1.53%)
NFLX   484.82 (-2.00%)
DIS   129.55 (-0.29%)
BAC   26.66 (+2.11%)
BA   177.74 (+4.54%)
Log in

NASDAQ:PTGXProtagonist Therapeutics Stock Price, Forecast & News

$18.00
+0.04 (+0.22 %)
(As of 08/10/2020 12:03 PM ET)
Add
Compare
Today's Range
$17.90
Now: $18.00
$18.16
50-Day Range
$15.19
MA: $16.88
$18.64
52-Week Range
$4.47
Now: $18.00
$19.67
Volume5,038 shs
Average Volume238,674 shs
Market Capitalization$493.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California.
Read More
Protagonist Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230,000.00
Book Value$2.94 per share

Profitability

Net Income$-77,190,000.00
Net Margins-438.96%

Miscellaneous

Employees64
Market Cap$493.74 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$18.00
+0.04 (+0.22 %)
(As of 08/10/2020 12:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

How has Protagonist Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PTGX shares have increased by 151.4% and is now trading at $18.00.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Protagonist Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protagonist Therapeutics
.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Protagonist Therapeutics
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by $0.03. The company had revenue of $3.65 million for the quarter, compared to the consensus estimate of $3.60 million. Protagonist Therapeutics had a negative net margin of 438.96% and a negative return on equity of 72.42%.
View Protagonist Therapeutics' earnings history
.

What price target have analysts set for PTGX?

6 brokerages have issued 12 month target prices for Protagonist Therapeutics' shares. Their forecasts range from $27.00 to $33.00. On average, they expect Protagonist Therapeutics' stock price to reach $30.00 in the next year. This suggests a possible upside of 66.7% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics
.

Has Protagonist Therapeutics been receiving favorable news coverage?

News articles about PTGX stock have been trending very positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protagonist Therapeutics earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Protagonist Therapeutics
.

Who are some of Protagonist Therapeutics' key competitors?

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), TG Therapeutics (TGTX), ImmunoGen (IMGN), Novavax (NVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Abeona Therapeutics (ABEO) and Energy Transfer LP Unit (ET).

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)
  • Dr. Richard S. Shames, Chief Medical Officer (Age 59)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)
  • Dr. Mark Smythe, VP of Technology (Age 54)
  • Dr. Samuel R. Saks, Chief Devel. Officer (Age 64)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.66%), UBS Group AG (0.25%), Bessemer Group Inc. (0.20%), WINTON GROUP Ltd (0.14%), Virtus ETF Advisers LLC (0.08%) and New York State Common Retirement Fund (0.08%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Harold E Selick, Richard S Shames and Suneel Gupta.
View institutional ownership trends for Protagonist Therapeutics
.

Which major investors are selling Protagonist Therapeutics stock?

PTGX stock was sold by a variety of institutional investors in the last quarter, including Trexquant Investment LP, and UBS Group AG.
View insider buying and selling activity for Protagonist Therapeutics
.

Which major investors are buying Protagonist Therapeutics stock?

PTGX stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bessemer Group Inc., Virtus ETF Advisers LLC, SG Americas Securities LLC, New York State Common Retirement Fund, Strs Ohio, WINTON GROUP Ltd, and Ameritas Investment Partners Inc.. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen, Harold E Selick, and Suneel Gupta.
View insider buying and selling activity for Protagonist Therapeutics
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $18.00.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $493.74 million and generates $230,000.00 in revenue each year. The company earns $-77,190,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.